Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may ac.

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences.

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Axsome Therapeutics

IO Biotech

One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regarding stock picks through the calculations of those deemed more experienced in understanding financial fundamentals.

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company.

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #hepatitisd--New data from Vir Biotechnology reinforces the potential for a transformative treatment for hepatitis delta, the most severe form of viral hepatitis.

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00 a.m. PT / 2:00 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir.

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company's Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. Dr. Eisner comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In.

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology's stockholders of record at the close of business on April 1, 2024, the record date for the Annual Meeting, can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareh.

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will hig.

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Science Applications International

BEAVERTON, Ore.--(BUSINESS WIRE)-- #familyfestivals--Reser's Fine Foods kicks off 2024 ‘Good Times Tour' with free delicious samples and fun activities in their booth at festivals throughout 2024.

Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE.

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

DURHAM, N.C. and BEIJING, May 13, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), an investigational HBV-targeting small interfering ribonucleic acid (siRNA).

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Alec Stranahan - Bank of America Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright Rosa Chen - Leerink Partners Joseph Stringer - Needham & Company Eric Joseph - JP Morgan Michaels Ulz - Morgan Stanley Operator Hello.

Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief.

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About.

Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024

Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Vir Biotechnology (VIR) a New Buy Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”). If elected, each of Drs. Bischofberger and Farid will join the Board on such date. The nomination of the two new independent directors demonstrates Vir's commitment to ongoing Board refreshment.

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of th.

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

Pyxis Oncology

Vertex Pharmaceuticals

Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

BioNTech SE

Immunocore Holdings

Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.

Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio

SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HepCantWait--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating t.

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.

News for Vir Biotechnology Stock (VIR)